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Scientific objectives
This study explores ways in which the requirements and
interrelationships between Personalized Medicine (PM),
clinical medical practice, and basic medical research
could be best served by information and communication
technologies (ICT). To avoid the problems inherent in
formulating ICT solutions in isolation, a use-case was
developed employing hepatocellular carcinoma (HCC).
The subject matter was approached from four separate,
but interrelated, tasks: (1) review of current understand-
ing and clinical practices relating to HCC; (2) propose
an ICT system for dealing with the vast amount of
information relating to HCC, including clinical decision
support and research needs; (3) determine the ways in
which a clinical liver cancer center can contribute to
this ICT approach; and, (4) examine the enhancements
and impact that the first three tasks, and therefore Per-
sonalized Medicine, will have on the management of
HCC. The development of an IT System for Persona-
lized Healthcare (ITS-PHC) for HCC will provide a
comprehensive system to identify and then determine
the relative value of the wide number of variables or
Information Entities (IEs): (1) factors reflecting clinical
assessment of the patient including functional status,
liver function, degree of cirrhosis, and comorbidities; (2)
factors reflecting tumor biology, at a molecular, genetic
and anatomic level; (3) factors reflecting tumor burden
and individual patient response; and (4) factors reflect-
ing medical and operative treatments and their
outcomes.
Technological approaches
It is our hypothesis, that if we can utilize patient-specific
modeling techniques to generate valid Digital Patient
Models (DPM) (utilizing these IEs) we may be able to
develop a statistically valid methodology for predicting
diseases, predicting treatment outcomes, preventing dis-
eases or complications, and developing personalized
treatment regimens. We are calling this proposed system
Model-Based Medical Evidence (MBME), and as yet
remains undeveloped. It is further postulated that Multi-
Entity Bayesian Networks (MEBN) used in the construc-
tion of the DPM will be utilized in the development of a
practical decision support system. Literature regarding
HCC was analyzed, combining epidemiology; risk fac-
tors; infectious etiologies; pathology, microenvironment
and biomarkers; screening and diagnostic technologies;
treatment modalities. IEs, that will be used to populate
the patient databases and MEBNs required for data
mining and decision support, were identifed. This infor-
mation was also used to reinforce a well-established
treatment protocol, i.e. the Barcelona treatment algo-
rithm, and, to add extensions that include enhanced
screening and greater specifics regarding treatment
selections.
Results interpretation
New algorithms are presented that relate to alternatives
in palliative treatments, down staging, and dealing with
progression of disease. Treatments for HCC included in
these algorithms include surgical resection, liver trans-
plantation, percutaneous ablation, transarterial che-
moembolization (TACE), local radiotherapy with
Yttrium-90 microspheres, stereotactic body radiation
therapy (SBRT), and systemic targeted therapy with the
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oral multikinase inhibitor, sorafenib. Currently, selection
of the best single form of therapy or a combination of
therapies, is unclear at this time, due insufficient avail-
able information. However, it is felt that as more
patients are entered into the ITS-PHC, and as detailed
Patient-Specific Models can be developed in sufficient
numbers, it will be possible to assess and validate the
treatment choices and criteria depicted in these algo-
rithms in a manner that heretofore has not been achiev-
able. Target benchmarks for the effective treatment of
hepatocellular carcinoma can be established. Compara-
tive studies of the costs of different treatment protocols
may be evaluated with respect to successes and failures
in treatment outcomes, and with respect to overall qual-
ity of care and the patient’s quality of life.
Outlook and expert recommendations
We hope that by giving greater emphasis to individual
patient characteristics and by extending the algorithms
to a wider range of the patient treatment continuum
(from screening to initial treatment to treatment of
recurrences to hospice care) that we can improve the
understanding, prevention, and treatment of HCC. We
hope that through the use of enhanced ICT it may be
possible to provide and validate a new methodology for
Evidence-Based Medicine utilizing model theory, i.e.
MBME. It is our assumption that the development of
improved Information Technology will promote an
approach based on a global understanding of disease
and treatment outcomes, rather than reliance primarily
upon local availability and expertise.
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